← All trials
NCT01813799
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2011
- Primary completion
- Aug 1, 2013
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 120
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Dong-A PharmaceuticalLead sponsor
- Inha UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Inje UniversityOverall official - principal investigator
- Chonnam National UniversityOverall official - principal investigator
- Sejong General HospitalOverall official - principal investigator
- Kyung Hee UniversityOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- Jeju National UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
- Kyungpook UniversityOverall official - principal investigator
- Daegu Catholic UniversityOverall official - principal investigator
- Pusan National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.